0
Skip to Content
Alaw Therapeutics
Management Team
Board of Directors
Scientific Advisory Board
Our Approach
Pipeline
News
Contact
Alaw Therapeutics
Management Team
Board of Directors
Scientific Advisory Board
Our Approach
Pipeline
News
Contact
Folder: Company
Back
Management Team
Board of Directors
Scientific Advisory Board
Our Approach
Pipeline
News
Contact
ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases
Sergey Kostikov 2025-12-22 Sergey Kostikov 2025-12-22

ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases

ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases

Read More
Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy
Sergey Kostikov 2025-10-24 Sergey Kostikov 2025-10-24

Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy

Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy

Read More

About Us
Our Approach
Pipeline
Contact

© 2026 Alaw Therapeutics Inc. All rights reserved.